Episode 557: The Stanford Scientist Rewriting the Future of Lyme Disease Treatment — Dr. Jayakumar Rajadas | Tick Boot Camp

In this groundbreaking episode of the Tick Boot Camp Podcast, we interview Dr. Jayakumar Rajadas, a Stanford Medicine researcher who has discovered multiple breakthrough therapeutic candidates for Lyme disease, Babesia, and Bartonella. His work includes the discovery of Disulfiram’s effectiveness against Lyme and Babesia, Azlocillin’s potent activity against Lyme and Bartonella, and advanced targeted drug-delivery systems designed to preserve the gut microbiome. Dr. Jay's research has been featured in TIME Magazine (Azlocillin) and Forbes (Disulfiram), and connects deeply with the work of leading Lyme researchers, including Dr. Monica Embers (Tulane), Dr. Kim Lewis (Northeastern), Dr. Kenneth Liegner, and Dr. Brian Fallon (Columbia University). This interview delivers hope, science, and unprecedented detail on what may become the next generation of Lyme disease treatments. Key Topics Covered 1. How the Stanford Tick Initiative Sparked a New Era of Drug Discovery In 2012, Stanford launched a major initiative in response to community demand for better Lyme treatments. Dr. Rajadas was selected to lead drug development, focusing specifically on persistent/chronic Lyme disease, where few researchers were working. 2. Understanding Borrelia: Active vs. Stationary Forms & Why Chronic Lyme Persists Dr. J explains the three key survival modes of Borrelia burgdorferi: Active Phase The bacteria are replicating and metabolically active. Easier to kill with standard antibiotics. Stationary Phase Bacteria reach population limits and slow down growth. Represents early persistence mechanisms. Persister Forms Triggered by stressors like antibiotics (e.g., doxycycline). Bacteria fold into round bodies, spiral forms, or compact “cement-like” protective balls. These forms: Shut down metabolic pathways Resist penetration Survive antibiotic exposure Why Doxycycline Can Fail Doxycycline can induce persisters, causing Borrelia to form impenetrable protective shells rather than die. This is why many patients initially feel better, then relapse. 3. Disulfiram (Antabuse): Lyme + Babesia Breakthrough Featured in Forbes One of the biggest scientific shocks of the last decade: Discovery Through Stanford’s high-throughput screening of FDA-approved drugs, Disulfiram emerged as a top hit. Clears Borrelia (including persistent forms) Clears Babesia — a major advantage over standard antibiotics Does NOT harm the gut microbiome Is already FDA-approved and widely used for alcohol aversion therapy Highly potent but requires careful dosing due to side effects in inflamed patients. Why Some Patients Improve, and Others Suffer Chronic Lyme patients already have heightened inflammation. Disulfiram is a powerful molecule whose polymorphic forms behave differently in different people. His lab developed: Less toxic formulations Buccal & sublingual delivery systems Rectal delivery options These may reduce neuropsychiatric side effects reported by some patients. Clinical Connections Dr. Kenneth Liegner pioneered clinical use and published cases Dr. Brian Fallon conducted NIH-listed clinical trials. Many clinicians now use Liegner’s protocols. Real-world example: Matt shares the story of Brooke Stoddard (Generation Lyme), who regained his life after Disulfiram treatment under Dr. Liegner. 4. Azlocillin: The Antibiotic That TIME Magazine Called a Gamechanger If Disulfiram is the Lyme and Babesia weapon, Azlocillin may be the frontline tool for Lyme and Bartonella. Why Azlocillin Is Revolutionary Eradicates both active and persister forms of Borrelia. Destroys doxycycline-induced “cement ball” persisters by drilling into their vulnerable cell-wall synthesis pathways. Proven effective against Bartonella when paired with azithromycin, based on research by Dr. Monica Embers (Tulane) . The Cell-Wall Vulnerability Breakthrough Persisters STILL must maintain minimal cell-wall synthesis to survive. Azlocillin exploits this tiny vulnerability: It penetrates the protective sphere Breaks the “cement wall” Forces the bacteria out of hibernation Kills them rapidly This discovery is one of the biggest scientific leaps in Lyme research in a decade. The Delivery System That Protects the Gut Microbiome Azlocillin is extremely hydrophilic, making absorption difficult.Dr. Jay fixed this by creating: A magnesium-lipid nanoparticle formulation Designed to release in the upper intestine Avoiding the colon (where most microbiome lives) This allows: High bloodstream absorption Minimal microbiome damage Oral availability of a drug previously only available via IV Why Azlocillin May Be Better Than Disulfiram Hits Borrelia + Bartonella Stronger anti-inflammatory effects No polymorphism issues Fewer side effects Potent against persisters A company is preparing to bring his oral formulation to clinical trials by next year. 5. Loratadine (Claritin): The First Clue from 2012 Before Disulfiram and ...